Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009-2013

Abstract

IMPORTANCE Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time. OBJECTIVE To investigate associations between televised DTCA and testosterone testing and initiation in the United States. DESIGN, SETTING, AND POPULATION Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-level testosterone use data from 2009-2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations. EXPOSURES Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs. MAIN OUTCOMES AND MEASURES (1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing. RESULTS Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment.Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95% CI, 1.004-1.008), initiation (RR, 1.007; 95% CI, 1.004-1.010), and initiation without a recent test (RR, 1.008; 95% CI, 1.002-1.013). Mean absolute rate increases were 0.14 tests (95% CI, 0.09-0.19), 0.05 new initiations (95% CI, 0.03-0.08), and 0.02 initiations without a recent test (95% CI, 0.01-0.03) per 10 000 men for each monthly ad exposure over the entire period.CONCLUSIONS AND RELEVANCE Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.

Overdiagnosis in primary care: framing the problem and finding solutions

“…Advertising is a powerful tool to facilitate disease mongering and foster overdiagnosis, as is shown in the case of Sarafem and others. In the US, direct-to-consumer advertising of testosterone replacement products was associated with testosterone testing and initiation of treatment with testosterone replacement therapy96; many of these cases probably represented overdiagnosis.…”

To T or not to T: Differences in Testosterone Use and Discontinuation by HIV Serostatus among Men who Have Sex with Men

“…In contrast, we were able to assess the effect upon TTh usage of characteristics measured prior to the discontinuation, albeit for a short period of follow‐up and without accounting for the duration of use prior to 2012. Ninety per cent of users self‐reported a testosterone deficiency, but our study did not include data on serum testosterone level monitoring among men before or after TTh initiation, which several studies have documented to be suboptimal . The key strengths of our study are the standardized characterization of TTh use, including participant motivations for use; the large multi‐city sample; and the prospective characterization of demographic, health and socio‐behavioural factors for both HIV‐infected and uninfected participants.…”

Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem

“…In actuality, only a minority of men who are prescribed testosterone are being properly evaluated for hypogonadism. In a study of men in the United States and United Kingdom, only 14% of men in the United Kingdom and 10% of the men in the United States had more than one testosterone test within 180 days of receiving a prescription for testosterone (28). Another study from the United States showed a similar result, with only 18% of men receiving at least two testosterone tests in the 12 months prior to initiating treatment (29).…”

“…In the United States, several pharmaceutical companies launched a highly successful disease awareness campaign for "low T" (28). The goal of this campaign was to increase the rates of testosterone testing and initiation, particularly among middle-and older-aged men, by leading men to believe that androgen deficiency could be a cause of their nonspecific symptoms.…”

“…Before 2012, Abbott Laboratories (now AbbVie) funded unbranded "low T" advertisements that were not FDA regulated. After 2012, competition for market share led AbbVie and Eli Lilly to promote brand-specific testosterone advertisements which were regulated by the FDA (28). According to Nielsen television ratings from the largest 75 designated market areas in the United States, the mean exposure to household advertisements for testosterone peaked in December 2012 at 13.6 advertisements/month (28).…”